The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects.
The effects of 2 weeks of lithium carbonate administration at therapeutic plasma levels were examined in 11 normal volunteers. Serotoninergic function before and after lithium administration was assessed using low-dose intravenous clomipramine hydrochloride challenge, while urinary and plasma metabolites of norepinephrine (NE) were used to assess noradrenergic systems. Long-term lithium administration in normal subjects did not significantly or consistently enhance serotonin-mediated neuroendocrine responses but did increase measures related to neuronal release of NE. No statistically significant effects of lithium on prolactin, corticotropin, or cortisol responses to serotoninergic challenge could be detected. The probability of a type II error was assessed, and a doubling of prolactin level was unlikely to have been missed, although more modest increases (less than 75%) could have been overlooked. After 2 weeks of lithium administration, there were significant increases in 24-hour urinary excretion of NE, normetanephrine, and fractional NE release, compatible with increased neuronal release of NE and a lithium-induced subsensitivity in alpha 2-adrenergic receptor function. These changes were not statistically significant after 1 week of administration, suggesting that increased NE release is characteristic of long- rather than short-term lithium administration. Since previous reports have demonstrated enhanced prolactin responses after short- but not long-term lithium use, the present study points to temporal specificity in lithium's effects on both serotoninergic and noradrenergic function. Lithium's effects on NE release were consistent but small (a 16% increase), while its effects on serotoninergic responses were larger (a 50% increase in prolactin responses) but quite inconsistent, suggesting that neither of these systems is the primary site of action of lithium.
Manji
H K
HK
Section on Clinical Pharmacology, National Institute of Mental Health, Bethesda, Md 20892.
Hsiao
J K
JK
Risby
E D
ED
Oliver
J
J
Rudorfer
M V
MV
Potter
W Z
WZ
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002997:Clomipramine / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007262:Infusions, Intravenous; D008094:Lithium / Q000494:pharmacology*; D016651:Lithium Carbonate; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine; D009638:Norepinephrine / Q000378:metabolism* / Q000652:urine; D009647:Normetanephrine / Q000652:urine; D011388:Prolactin / Q000097:blood; D011941:Receptors, Adrenergic / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000502:physiology*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D014642:Vanilmandelic Acid / Q000652:urine
D011941:Receptors, Adrenergic; D011985:Receptors, Serotonin; D009647:Normetanephrine; D016651:Lithium Carbonate; D012701:Serotonin; D008734:Methoxyhydroxyphenylglycol; D014642:Vanilmandelic Acid; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D008094:Lithium; D002997:Clomipramine; D006854:Hydrocortisone; D009638:Norepinephrine